KIR3DL2 and hepatitis B virus infection: Specifically, 10 potential therapeutic targets (AKT1, CASP3, IL6, JUN, MYC, MAPK3, SRC, STAT3, TNF, TP53) were directly linked to the KEGG pathway “hepatitis B” and were associated with 21 compounds (SQ7, ZJ11, ZJ3, ZJ4, CBM9, CF2, CF3, QYS8, QYS9, ZJ8, CL3, CL5, ZZS1, CL2, DSL4, ZJ10, ZJ6, DSL5, JTS1, TM12, XYS18; Table S2).